Lukatch Heath 4
4 · Vaxcyte, Inc. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Lukatch Heath
Director
Transactions
- Exercise/Conversion
Common Stock
2024-01-02$16.00/sh+13,000$208,000→ 18,625 total - Sale
Common Stock
2024-01-02$62.85/sh−1,101$69,201→ 17,524 total - Sale
Common Stock
2024-01-02$64.28/sh−4,164$267,662→ 5,916 total - Sale
Common Stock
2024-01-02$63.55/sh−7,444$473,081→ 10,080 total - Exercise/Conversion
Stock Option (right to buy)
2024-01-02−13,000→ 15,000 totalExercise: $16.00Exp: 2030-06-10→ Common Stock (13,000 underlying) - Sale
Common Stock
2024-01-02$65.19/sh−291$18,971→ 5,625 total
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $63.01 to $64.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $64.015 to $64.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported is a weighted-average price. The shares were sold at prices ranging from $65.12 to $65.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Fully vested and exercisable.